Bedaquiline Fumarate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Bedaquiline Fumarate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
119
Registered trials
52
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Bedaquiline Fumarate can convert its Small molecule drug profile and mycobacterial ATP synthase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Bedaquiline Fumarate (query alias: bedaquiline) |
|---|---|
| Modality / target | Small molecule drug; mycobacterial ATP synthase; mycobacterial ATP synthase inhibitors |
| Highest global status | Approved |
| Originator | Janssen Global Services LLC |
| Active developers | Janssen Korea Ltd., Janssen Research & Development LLC, Janssen-Cilag International NV |
The MCP disease footprint includes Pulmonary Tuberculosis, Tuberculosis, Multidrug resistant pulmonary tuberculosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07675954 | Phase 3 | Not yet recruiting | 294 | Favourable outcome at 12 months after treatment discontinuation |
| NCT07517445 | Phase 2 | Recruiting | 165 | Bactericidal Activity |
| NCT07525427 | Phase 2 | Recruiting | 150 | Bactericidal Activity |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis
Phase 2; n=309; evaluation: not stated. Reported fields: Proportion of Participants With Stable Sputum Conversion by 8 Weeks,(Mean) = 0.593 proportion of participants (95% Confidence Interval, 0.472 - 0.718); Proportion of Participants With Stable Sputum Conversion by 8 Weeks,(Mean) = 0.476 proportion of participants (95% Confidence Interval, 0.362 - 0.606); -
A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis
Phase 2; n=93; evaluation: not stated. Reported fields: -; ≥ Grade 3 TEAEs At Week 19 = 16.7 percentage of participants ; -
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
Phase 2/3; n=121; evaluation: Positive. Reported fields: SCC(end of treatment) = 96.0 % ( 90.1 - 98.9); -; SCC(end of treatment) = 100.0 % ( 83.2 - 100.0)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Bedaquiline Fumarate addresses Pulmonary Tuberculosis, Tuberculosis, Multidrug resistant pulmonary tuberculosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: mycobacterial ATP synthase records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2018-04-24 | 辰欣药业与上海嘉坦医药科技有限公司签署独家授许及合作开发协议 | IND Application | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of bedaquiline fumarate”. The milestone feed surfaced a patent-application signal described as “Method for monitoring serum concentrations of bedaquiline for assessing effectiveness of Anti-tuberculosis chemotherapy”. The milestone feed surfaced a patent-application signal described as “Method for chiral synthesis of (1R, 2S)-bedaquiline”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
